MannKind Killed After Earnings (MNKD)

Mannkind

, whose AFREZZA insulin delivery device was recently rejected by the FDA, released its quarterly earnings after the closing bell on Thursday. The company reported a loss of $0.33 per share versus analysts' estimates which called for a loss of $0.40 per share. In the year ago period, MNKD lost $0.53. During Friday's trading session, the stock has been obliterated, losing more than 25% to $3.81. Volume is running at around 15 million shares compared to a daily average of 5 million. MNKD is a wounded company at this point, having lost around 56% in the last month.